AN UNDETECTABLE PB MRD STATUS SHOULD BE THE THERAPEUTIC GOAL WITH VENETOCLAX THERAPY IN RELAPSED/ REFRACTORY CLL

S.M. Handunnetti,T.E. Lew, V.S. Lin,M.A. Anderson,D. Carney,M. Wolf,N. Came,S. Juneja,D. Westerman,C.S. Tam,A.W. Roberts,J.F. Seymour

Hematological oncology（2019）

引用 0|浏览40

暂无评分

摘要

Genentech; Stock Ownership: Hoffmann–La Roche. Boyer, M: Employment Leadership Position: Roche; Stock Ownership: Roche. Humphrey, K: Employment Leadership Position: Roche; Stock Ownership: Roche. Jiang, Y: Employment Leadership Position: Genentech; Stock Ownership: Genentech. Kater, A: Consultant Advisory Role: AbbVie; Honoraria: Abbvie; Research Funding: Genetech, Roche, AbbVie; Other Remuneration: Travel, accommodations, expenses: Roche.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要